Company Filing History:
1 out of 230 
1 out of 263 Years Active: 2021
Title: Kristin M Goldberg: Innovator in Cancer Treatment
Introduction
Kristin M Goldberg is a notable inventor based in Manchester, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target DNMT1, a key enzyme involved in various diseases.
Latest Patents
Kristin holds a patent for "Substituted pyridines as inhibitors of DNMT1." This invention focuses on substituted pyridine derivatives, specifically compounds that are selective inhibitors of DNMT1. These compounds can be beneficial in treating cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia. The invention also encompasses pharmaceutical compositions that include these compounds and methods for inhibiting DNMT1 activity.
Career Highlights
Throughout her career, Kristin has worked with prominent organizations such as GlaxoSmithKline Intellectual Property Development Limited and Cancer Research Technology Limited. Her work has been instrumental in advancing research and development in the pharmaceutical industry.
Collaborations
Kristin has collaborated with notable professionals in her field, including Nicholas D Adams and Andrew B Benowitz. These partnerships have contributed to her innovative work and the successful development of her patented compounds.
Conclusion
Kristin M Goldberg is a pioneering inventor whose work in developing DNMT1 inhibitors holds promise for treating various serious health conditions. Her contributions to the pharmaceutical industry continue to impact the field positively.